Listed

Coya Therapeutics, Inc.

COYANasdaqCIK 1835022HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$243.7k, Q2 FY2026
Operating income−$7.0m, Q2 FY2026
Net income−$6.6m, Q2 FY2026
Coya Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$k0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure6,002Revenue, Q4 FY2023, three months to 2023-12-31$6.0m. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-18, accession 0000950170-25-040782. Derived: 12-month figure less the 9-month figure.Report this figure127Revenue, Q1 FY2024, three months to 2024-03-31$126.8k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure3,425Revenue, Q2 FY2024, three months to 2024-06-30$3.4m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure2.0Revenue, Q4 FY2024, three months to 2024-12-31$2.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001193125-26-107281. Derived: 12-month figure less the 9-month figure.Report this figure258Revenue, Q1 FY2025, three months to 2025-03-31$257.9k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure164Revenue, Q2 FY2025, three months to 2025-06-30$163.6k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure3,564Revenue, Q3 FY2025, three months to 2025-09-30$3.6m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure3,960Revenue, Q4 FY2025, three months to 2025-12-31$4.0m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001193125-26-107281. Derived: 12-month figure less the 9-month figure.Report this figure251Revenue, Q1 FY2026, three months to 2026-03-31$251.1k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure244Revenue, Q2 FY2026, three months to 2026-06-30$243.7k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure
Operating income$k(3,564)Operating income, Q3 FY2023, three months to 2023-09-30−$3.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure1,815Operating income, Q4 FY2023, three months to 2023-12-31$1.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-18, accession 0000950170-25-040782. Derived: 12-month figure less the 9-month figure.Report this figure(5,483)Operating income, Q1 FY2024, three months to 2024-03-31−$5.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure(3,236)Operating income, Q2 FY2024, three months to 2024-06-30−$3.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figure(4,450)Operating income, Q3 FY2024, three months to 2024-09-30−$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure(4,080)Operating income, Q4 FY2024, three months to 2024-12-31−$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107281. Derived: 12-month figure less the 9-month figure.Report this figure(7,677)Operating income, Q1 FY2025, three months to 2025-03-31−$7.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure(6,415)Operating income, Q2 FY2025, three months to 2025-06-30−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure(2,433)Operating income, Q3 FY2025, three months to 2025-09-30−$2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure(6,031)Operating income, Q4 FY2025, three months to 2025-12-31−$6.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107281. Derived: 12-month figure less the 9-month figure.Report this figure(7,640)Operating income, Q1 FY2026, three months to 2026-03-31−$7.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure(7,047)Operating income, Q2 FY2026, three months to 2026-06-30−$7.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure
Income tax$knot reportednot reportednot reported0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figurenot reportednot reportednot reported0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figurenot reportednot reportednot reportednot reported
Net income$k(3,422)Net income, Q3 FY2023, three months to 2023-09-30−$3.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure1,266Net income, Q4 FY2023, three months to 2023-12-31$1.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-18, accession 0000950170-25-040782. Derived: 12-month figure less the 9-month figure.Report this figure(5,052)Net income, Q1 FY2024, three months to 2024-03-31−$5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure(2,892)Net income, Q2 FY2024, three months to 2024-06-30−$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure(4,021)Net income, Q3 FY2024, three months to 2024-09-30−$4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure(2,916)Net income, Q4 FY2024, three months to 2024-12-31−$2.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107281. Derived: 12-month figure less the 9-month figure.Report this figure(7,307)Net income, Q1 FY2025, three months to 2025-03-31−$7.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure(6,095)Net income, Q2 FY2025, three months to 2025-06-30−$6.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure(2,116)Net income, Q3 FY2025, three months to 2025-09-30−$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure(5,709)Net income, Q4 FY2025, three months to 2025-12-31−$5.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001193125-26-107281. Derived: 12-month figure less the 9-month figure.Report this figure(7,207)Net income, Q1 FY2026, three months to 2026-03-31−$7.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure(6,638)Net income, Q2 FY2026, three months to 2026-06-30−$6.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure
Diluted EPS$ per share(0.34)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figurenot reported(0.35)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure(0.19)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figure(0.26)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figurenot reported(0.44)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure(0.36)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure(0.13)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figurenot reported(0.32)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure(0.28)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure
Basic EPS$ per share(0.34)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figurenot reported(0.35)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure(0.19)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figure(0.26)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figurenot reported(0.44)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure(0.36)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure(0.13)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figurenot reported(0.32)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.32 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure(0.28)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure

Balance sheet

Cash and equivalents$43.2m, Q2 FY2026
Shareholders' equity$43.3m, Q2 FY2026
Coya Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m10.9Cash and equivalents, Q3 FY2023, at 2023-09-30$10.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-08, accession 0000950170-23-060718.Report this figure32.6Cash and equivalents, FY2023, at 2023-12-31$32.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-18, accession 0000950170-25-040782.Report this figure36.0Cash and equivalents, Q1 FY2024, at 2024-03-31$36.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0000950170-24-057056.Report this figure36.6Cash and equivalents, Q2 FY2024, at 2024-06-30$36.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-12, accession 0000950170-24-095075.Report this figure31.1Cash and equivalents, Q3 FY2024, at 2024-09-30$31.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure38.3Cash and equivalents, FY2024, at 2024-12-31$38.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-16, accession 0001193125-26-107281.Report this figure35.5Cash and equivalents, Q1 FY2025, at 2025-03-31$35.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure29.8Cash and equivalents, Q2 FY2025, at 2025-06-30$29.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figure28.1Cash and equivalents, Q3 FY2025, at 2025-09-30$28.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure46.8Cash and equivalents, FY2025, at 2025-12-31$46.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure50.7Cash and equivalents, Q1 FY2026, at 2026-03-31$50.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure43.2Cash and equivalents, Q2 FY2026, at 2026-06-30$43.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure
Current assets$m11.8Current assets, Q3 FY2023, at 2023-09-30$11.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-08, accession 0000950170-23-060718.Report this figure41.2Current assets, FY2023, at 2023-12-31$41.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-18, accession 0000950170-25-040782.Report this figure37.3Current assets, Q1 FY2024, at 2024-03-31$37.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-057056.Report this figure39.9Current assets, Q2 FY2024, at 2024-06-30$39.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-12, accession 0000950170-24-095075.Report this figure35.5Current assets, Q3 FY2024, at 2024-09-30$35.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure44.3Current assets, FY2024, at 2024-12-31$44.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-16, accession 0001193125-26-107281.Report this figure38.4Current assets, Q1 FY2025, at 2025-03-31$38.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure33.4Current assets, Q2 FY2025, at 2025-06-30$33.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figure32.0Current assets, Q3 FY2025, at 2025-09-30$32.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure49.9Current assets, FY2025, at 2025-12-31$49.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure53.3Current assets, Q1 FY2026, at 2026-03-31$53.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure47.1Current assets, Q2 FY2026, at 2026-06-30$47.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure
Total assets$m11.9Total assets, Q3 FY2023, at 2023-09-30$11.9m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-08, accession 0000950170-23-060718.Report this figure41.3Total assets, FY2023, at 2023-12-31$41.3m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-18, accession 0000950170-25-040782.Report this figure37.4Total assets, Q1 FY2024, at 2024-03-31$37.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0000950170-24-057056.Report this figure39.9Total assets, Q2 FY2024, at 2024-06-30$39.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-12, accession 0000950170-24-095075.Report this figure35.6Total assets, Q3 FY2024, at 2024-09-30$35.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure44.3Total assets, FY2024, at 2024-12-31$44.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-16, accession 0001193125-26-107281.Report this figure38.4Total assets, Q1 FY2025, at 2025-03-31$38.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure33.5Total assets, Q2 FY2025, at 2025-06-30$33.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figure32.0Total assets, Q3 FY2025, at 2025-09-30$32.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure50.0Total assets, FY2025, at 2025-12-31$50.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure53.3Total assets, Q1 FY2026, at 2026-03-31$53.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure47.3Total assets, Q2 FY2026, at 2026-06-30$47.3m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure
Current liabilities$m1.8Current liabilities, Q3 FY2023, at 2023-09-30$1.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-08, accession 0000950170-23-060718.Report this figure5.1Current liabilities, FY2023, at 2023-12-31$5.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-18, accession 0000950170-25-040782.Report this figure4.3Current liabilities, Q1 FY2024, at 2024-03-31$4.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-057056.Report this figure3.8Current liabilities, Q2 FY2024, at 2024-06-30$3.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-12, accession 0000950170-24-095075.Report this figure2.3Current liabilities, Q3 FY2024, at 2024-09-30$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure3.8Current liabilities, FY2024, at 2024-12-31$3.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-16, accession 0001193125-26-107281.Report this figure4.3Current liabilities, Q1 FY2025, at 2025-03-31$4.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure4.5Current liabilities, Q2 FY2025, at 2025-06-30$4.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figure3.7Current liabilities, Q3 FY2025, at 2025-09-30$3.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure5.9Current liabilities, FY2025, at 2025-12-31$5.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure3.5Current liabilities, Q1 FY2026, at 2026-03-31$3.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure3.5Current liabilities, Q2 FY2026, at 2026-06-30$3.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure
Total liabilities$m1.8Total liabilities, Q3 FY2023, at 2023-09-30$1.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-08, accession 0000950170-23-060718.Report this figure5.6Total liabilities, FY2023, at 2023-12-31$5.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-18, accession 0000950170-25-040782.Report this figure5.0Total liabilities, Q1 FY2024, at 2024-03-31$5.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0000950170-24-057056.Report this figure4.7Total liabilities, Q2 FY2024, at 2024-06-30$4.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-12, accession 0000950170-24-095075.Report this figure3.5Total liabilities, Q3 FY2024, at 2024-09-30$3.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure4.8Total liabilities, FY2024, at 2024-12-31$4.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-16, accession 0001193125-26-107281.Report this figure5.0Total liabilities, Q1 FY2025, at 2025-03-31$5.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure5.1Total liabilities, Q2 FY2025, at 2025-06-30$5.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figure4.8Total liabilities, Q3 FY2025, at 2025-09-30$4.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure6.9Total liabilities, FY2025, at 2025-12-31$6.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure4.3Total liabilities, Q1 FY2026, at 2026-03-31$4.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure4.0Total liabilities, Q2 FY2026, at 2026-06-30$4.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure
Shareholders' equity$m10.1Shareholders' equity, Q3 FY2023, at 2023-09-30$10.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure35.6Shareholders' equity, FY2023, at 2023-12-31$35.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-16, accession 0001193125-26-107281.Report this figure32.4Shareholders' equity, Q1 FY2024, at 2024-03-31$32.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure35.3Shareholders' equity, Q2 FY2024, at 2024-06-30$35.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure32.0Shareholders' equity, Q3 FY2024, at 2024-09-30$32.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure39.6Shareholders' equity, FY2024, at 2024-12-31$39.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure33.4Shareholders' equity, Q1 FY2025, at 2025-03-31$33.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure28.3Shareholders' equity, Q2 FY2025, at 2025-06-30$28.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure27.3Shareholders' equity, Q3 FY2025, at 2025-09-30$27.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure43.0Shareholders' equity, FY2025, at 2025-12-31$43.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure49.0Shareholders' equity, Q1 FY2026, at 2026-03-31$49.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure43.3Shareholders' equity, Q2 FY2026, at 2026-06-30$43.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure

Cash flow

Operating cash flow−$7.4m, Q2 FY2026
Coya Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(2,216)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-06, accession 0000950170-24-121837. Derived: 9-month figure less the 6-month figure.Report this figure(2,241)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$2.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-18, accession 0000950170-25-040782. Derived: 12-month figure less the 9-month figure.Report this figure2,146Operating cash flow, Q1 FY2024, three months to 2024-03-31$2.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure(4,564)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$4.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-12, accession 0000950170-25-106934. Derived: 6-month figure less the 3-month figure.Report this figure(5,461)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-276058. Derived: 9-month figure less the 6-month figure.Report this figure(2,410)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$2.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-107281. Derived: 12-month figure less the 9-month figure.Report this figure(2,828)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$2.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure(5,773)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-343481. Derived: 6-month figure less the 3-month figure.Report this figure(1,131)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-276058. Derived: 9-month figure less the 6-month figure.Report this figure(1,007)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$1.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001193125-26-107281. Derived: 12-month figure less the 9-month figure.Report this figure(6,209)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$6.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure(7,376)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$7.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-343481. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)23.46m, Q2 FY2026
Coya Therapeutics, Inc., shares, quarterly
Line itemUnitperiod not labelled2022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares2.6Diluted shares (weighted), period not labelled, three months to 2022-09-302,590,197 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-08, accession 0000950170-23-060718.Report this figure9.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-319,721,847 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0000950170-24-057056.Report this figure9.9Diluted shares (weighted), Q2 FY2023, three months to 2023-06-309,947,915 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-12, accession 0000950170-24-095075.Report this figure9.9Diluted shares (weighted), Q3 FY2023, three months to 2023-09-309,947,915 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-06, accession 0000950170-24-121837.Report this figure14.5Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3114,457,839 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0000950170-25-069824.Report this figure14.9Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3014,915,217 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-12, accession 0000950170-25-106934.Report this figure15.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3015,221,308 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure16.7Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3116,720,511 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure16.7Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3016,724,998 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure16.7Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3016,732,766 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-276058.Report this figure22.6Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3122,644,304 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-218201.Report this figure23.5Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3023,457,227 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure

Shares outstanding: 23.46mShares outstanding, period not labelled, at 2026-08-0723,457,849 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-343481.Report this figure at Aug 7, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.